OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2019) Vol. 11, Iss. 2, pp. 369-386
Open Access | Times Cited: 59
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2019) Vol. 11, Iss. 2, pp. 369-386
Open Access | Times Cited: 59
Showing 1-25 of 59 citing articles:
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 6, pp. 1199-1216
Open Access | Times Cited: 166
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 6, pp. 1199-1216
Open Access | Times Cited: 166
Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations
David M. Williams, Hannah Jones, Jeffrey W. Stephens
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 281-295
Open Access | Times Cited: 76
David M. Williams, Hannah Jones, Jeffrey W. Stephens
Diabetes Metabolic Syndrome and Obesity (2022) Vol. Volume 15, pp. 281-295
Open Access | Times Cited: 76
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Józef Drzewoski, M Hanefeld
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 122-122
Open Access | Times Cited: 101
Józef Drzewoski, M Hanefeld
Pharmaceuticals (2021) Vol. 14, Iss. 2, pp. 122-122
Open Access | Times Cited: 101
New Molecules in Type 2 Diabetes: Advancements, Challenges and Future Directions
Kyriazoula Chatzianagnostou, Melania Gaggini, Adrian Suman Florentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6218-6218
Open Access | Times Cited: 8
Kyriazoula Chatzianagnostou, Melania Gaggini, Adrian Suman Florentin, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 6218-6218
Open Access | Times Cited: 8
Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
Soghra Rabizadeh, Manouchehr Nakhjavani, Alireza Esteghamati
International Journal of Endocrinology and Metabolism (2019) Vol. In Press, Iss. In Press
Open Access | Times Cited: 57
Soghra Rabizadeh, Manouchehr Nakhjavani, Alireza Esteghamati
International Journal of Endocrinology and Metabolism (2019) Vol. In Press, Iss. In Press
Open Access | Times Cited: 57
From Obesity to Chronic Kidney Disease: How Can Adipose Tissue Affect Renal Function?
Marina Martín-Taboada, Rocío Vila‐Bedmar, Gema Medina‐Gómez
The Nephron journals/Nephron journals (2021) Vol. 145, Iss. 6, pp. 609-613
Open Access | Times Cited: 48
Marina Martín-Taboada, Rocío Vila‐Bedmar, Gema Medina‐Gómez
The Nephron journals/Nephron journals (2021) Vol. 145, Iss. 6, pp. 609-613
Open Access | Times Cited: 48
Insulin: Trigger and Target of Renal Functions
Ana F. Pina, Diego Olschowsky Borges, Maria João Meneses, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 46
Ana F. Pina, Diego Olschowsky Borges, Maria João Meneses, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 46
Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 10, pp. 2207-2219
Open Access | Times Cited: 46
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 10, pp. 2207-2219
Open Access | Times Cited: 46
Inter‐relationships between cardiovascular, renal and metabolic diseases: Underlying evidence and implications for integrated interdisciplinary care and management
Jiten Vora, David Z.I. Cherney, Mikhail Kosiborod, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 5, pp. 1567-1581
Closed Access | Times Cited: 4
Jiten Vora, David Z.I. Cherney, Mikhail Kosiborod, et al.
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 5, pp. 1567-1581
Closed Access | Times Cited: 4
AMPK-Mediated Multi-Organ Protective Effects of GLP-1 Receptor Agonists
Xin Wang, Linxi Wang
(2025), pp. 4-4
Closed Access
Xin Wang, Linxi Wang
(2025), pp. 4-4
Closed Access
Care pathways for patients with cognitive impairment and chronic kidney disease
Marion Pépin, Konstantinos Giannakou, Hélène Levassort, et al.
Nephrology Dialysis Transplantation (2025) Vol. 40, Iss. Supplement_2, pp. ii28-ii36
Open Access
Marion Pépin, Konstantinos Giannakou, Hélène Levassort, et al.
Nephrology Dialysis Transplantation (2025) Vol. 40, Iss. Supplement_2, pp. ii28-ii36
Open Access
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 12, Iss. 1, pp. 55-70
Open Access | Times Cited: 31
David M. Williams, Asif Nawaz, Marc Evans
Diabetes Therapy (2020) Vol. 12, Iss. 1, pp. 55-70
Open Access | Times Cited: 31
Comorbidities and complications in Japanese patients with type 2 diabetes mellitus: Retrospective analyses of J-DREAMS, an advanced electronic medical records database
Mitsuru Ohsugi, Jun‐ichi Eiki, Kristy Iglay, et al.
Diabetes Research and Clinical Practice (2021) Vol. 178, pp. 108845-108845
Open Access | Times Cited: 23
Mitsuru Ohsugi, Jun‐ichi Eiki, Kristy Iglay, et al.
Diabetes Research and Clinical Practice (2021) Vol. 178, pp. 108845-108845
Open Access | Times Cited: 23
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Evangelia Makri, A. Goulas, Stergios A. Pοlyzos
European Journal of Pharmacology (2021) Vol. 907, pp. 174272-174272
Closed Access | Times Cited: 20
Evangelia Makri, A. Goulas, Stergios A. Pοlyzos
European Journal of Pharmacology (2021) Vol. 907, pp. 174272-174272
Closed Access | Times Cited: 20
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Adie Viljoen, Stephen C. Bain
Endocrinology and Metabolism (2023) Vol. 38, Iss. 1, pp. 25-33
Open Access | Times Cited: 7
Adie Viljoen, Stephen C. Bain
Endocrinology and Metabolism (2023) Vol. 38, Iss. 1, pp. 25-33
Open Access | Times Cited: 7
Stroke Prevention and Treatment in People With Type 2 Diabetes: Is There a Role for GLP-1 (Glucagon-Like Peptide-1) Analogues?
David M. Williams, Michael Atkinson, Marc Evans
Stroke (2023) Vol. 54, Iss. 5, pp. 1441-1451
Closed Access | Times Cited: 7
David M. Williams, Michael Atkinson, Marc Evans
Stroke (2023) Vol. 54, Iss. 5, pp. 1441-1451
Closed Access | Times Cited: 7
Advances in the management of diabetes: therapies for type 2 diabetes
Jovanna Tsoutsouki, Wunna Wunna, A A Chowdhury, et al.
Postgraduate Medical Journal (2020) Vol. 96, Iss. 1140, pp. 610-618
Open Access | Times Cited: 20
Jovanna Tsoutsouki, Wunna Wunna, A A Chowdhury, et al.
Postgraduate Medical Journal (2020) Vol. 96, Iss. 1140, pp. 610-618
Open Access | Times Cited: 20
A look to the future in non‐alcoholic fatty liver disease: Are glucagon‐like peptide‐1 analogues or sodium‐glucose co‐transporter‐2 inhibitors the answer?
Rebecca Vincent, David M. Williams, Marc Evans
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2227-2240
Open Access | Times Cited: 18
Rebecca Vincent, David M. Williams, Marc Evans
Diabetes Obesity and Metabolism (2020) Vol. 22, Iss. 12, pp. 2227-2240
Open Access | Times Cited: 18
Diabetic kidney disease in children and adolescents: an update
Lauren N. Lopez, Wei-Jie Wang, Lindsey A. Loomba, et al.
Pediatric Nephrology (2021) Vol. 37, Iss. 11, pp. 2583-2597
Open Access | Times Cited: 16
Lauren N. Lopez, Wei-Jie Wang, Lindsey A. Loomba, et al.
Pediatric Nephrology (2021) Vol. 37, Iss. 11, pp. 2583-2597
Open Access | Times Cited: 16
Metainflammation in COVID-19
Mojtaba Bakhtiari, Kamyar Asadipooya
Endocrine Metabolic & Immune Disorders - Drug Targets (2022) Vol. 22, Iss. 12, pp. 1154-1166
Closed Access | Times Cited: 11
Mojtaba Bakhtiari, Kamyar Asadipooya
Endocrine Metabolic & Immune Disorders - Drug Targets (2022) Vol. 22, Iss. 12, pp. 1154-1166
Closed Access | Times Cited: 11
Absolute treatment effects of novel antidiabetic drugs on a composite renal outcome: meta-analysis of digitalized individual patient data
Maximilian Brockmeyer, Claudio Parco, Kris Gregory Vargas, et al.
Journal of Nephrology (2024) Vol. 37, Iss. 2, pp. 309-321
Open Access | Times Cited: 2
Maximilian Brockmeyer, Claudio Parco, Kris Gregory Vargas, et al.
Journal of Nephrology (2024) Vol. 37, Iss. 2, pp. 309-321
Open Access | Times Cited: 2
Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 9, pp. 1925-1934
Open Access | Times Cited: 16
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 9, pp. 1925-1934
Open Access | Times Cited: 16
Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 10, pp. 2221-2235
Open Access | Times Cited: 16
David M. Williams, Marc Evans
Diabetes Therapy (2020) Vol. 11, Iss. 10, pp. 2221-2235
Open Access | Times Cited: 16
<p>Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations</p>
Mohamed Hassan Elnaem, Noha O. Mansour, Abdul Rahman Fata Nahas, et al.
International Journal of General Medicine (2020) Vol. Volume 13, pp. 1395-1409
Open Access | Times Cited: 16
Mohamed Hassan Elnaem, Noha O. Mansour, Abdul Rahman Fata Nahas, et al.
International Journal of General Medicine (2020) Vol. Volume 13, pp. 1395-1409
Open Access | Times Cited: 16
New American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) guidelines for the pharmacotherapy of type 2 diabetes: Placing them into a practicing physician's perspective
Niki Katsiki, Ele Ferrannini, Christos S. Mantzoros
Metabolism (2020) Vol. 107, pp. 154218-154218
Closed Access | Times Cited: 15
Niki Katsiki, Ele Ferrannini, Christos S. Mantzoros
Metabolism (2020) Vol. 107, pp. 154218-154218
Closed Access | Times Cited: 15
